Next-Generation Sequencing (NGS) is a huge leap in the fight against cancer, but even experienced physicians and oncologists may not be familiar with the latest advances in personalized medicine. PathGroup's new NGS technology is bringing costs down for patients and providers with a revolutionary new assay that yields more information with smaller samples. We helped PathGroup make a complex subject simple and understandable in a way that kept physicians engaged while creating a common narrative that everyone could share, positioning their brand and solution as category leaders. 
Back to Top